QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 adma-biologics-sees-fy2026-sales-500000m-625000m-vs-64117m-est

ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $500.000 million-$625.000 million vs $641.17 million analyst estimate.

 adma-biologics-sees-fy2025-sales-500000m-625000m-vs-50767m-est

ADMA Biologics (NASDAQ:ADMA) sees FY2025 sales of $500.000 million-$625.000 million vs $507.67 million analyst estimate.

 adma-biologics-q2-adj-eps-014-inline-sales-12198m-miss-12267m-estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.14 per share which met the analyst consensus estimate. This is a...

 raymond-james-maintains-strong-buy-on-adma-biologics-raises-price-target-to-32

Raymond James analyst Elliot Wilbur maintains ADMA Biologics (NASDAQ:ADMA) with a Strong Buy and raises the price target fro...

 adma-biologics-fy2026--revenue-expected-to-be-more-than-62500m-vs-62923m-est

ADMA Biologics (NASDAQ:ADMA) FY2026 Revenue expected to be more than $625.00M vs $629.23M Est

 adma-biologics-fy2025--revenue-expected-to-be-more-than-50000m-vs-49510m-est

ADMA Biologics (NASDAQ:ADMA) FY2025 Revenue expected to be more than $500.00M vs $495.10M Est

 adma-biologics-q1-adj-eps-014-misses-016-estimate-sales-11480m-miss-11640m-estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.1...

 adma-biologics-earnings-preview
ADMA Biologics Earnings Preview
05/06/2025 15:01:20

 whats-going-on-with-adma-stock-monday

ADM shares are trading higher Monday after the company announced the FDA's approval of its yield enhancement process.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION